JY
GLUE icon

Jeff Yass’s Monte Rosa Therapeutics GLUE Stock Holding History

Jeff Yass’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$886K Sell
36,600
-57,900
-61% -$1.09M ﹤0.01% 8497
2026
Q1 		$1.55M Sell
94,500
-18,200
-16% -$348K ﹤0.01% 6783
2025
Q4 		$1.77M Sell
112,700
-8,200
-7% -$110K ﹤0.01% 5907
2025
Q3 		$896K Buy
120,900
+109,100
+925% +$578K ﹤0.01% 7598
2025
Q2 		$53.2K Sell
11,800
-22,400
-65% -$99.9K ﹤0.01% 12088
2025
Q1 		$159K Sell
34,200
-159,300
-82% -$977K ﹤0.01% 11176
2024
Q4 		$1.34M Buy
193,500
+122,400
+172% +$919K ﹤0.01% 6230
2024
Q3 		$377K Sell
71,100
-1,400
-2% -$7.07K ﹤0.01% 9112
2024
Q2 		$271K Buy
72,500
+7,500
+12% +$38.2K ﹤0.01% 9675
2024
Q1 		$458K Sell
65,000
-46,100
-41% -$273K ﹤0.01% 8704
2023
Q4 		$628K Buy
111,100
+80,000
+257% +$314K ﹤0.01% 8112
2023
Q3 		$149K Buy
31,100
+9,400
+43% +$60.5K ﹤0.01% 10548
2023
Q2 		$149K Sell
21,700
-1,100
-5% -$7.11K ﹤0.01% 10589
2023
Q1 		$178K Sell
22,800
-12,300
-35% -$85.5K ﹤0.01% 10737
2022
Q4 		$267K Buy
+35,100
New +$292K ﹤0.01% 9388

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's GLUE Position: Q2 2026 in Review

Jeff Yass increased its Monte Rosa Therapeutics (GLUE) stake by 39% in Q2 2026, buying an estimated $180K and bringing the position to 34,281 shares worth $830K. The position accounts for ﹤0.01% of the portfolio, ranked #8680.

Jeff Yass first reported a position in GLUE in Q2 2022 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Jeff Yass held 34,281 shares of Monte Rosa Therapeutics worth $830K as of Q2 2026.
  • Jeff Yass bought 9,530 Monte Rosa Therapeutics shares in Q2 2026, an estimated $180K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8680 holding.
  • Jeff Yass first reported a position in Monte Rosa Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.